280 related articles for article (PubMed ID: 28667550)
1. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers.
Tassorelli C; Aguggia M; De Tommaso M; Geppetti P; Grazzi L; Pini LA; Sarchielli P; Tedeschi G; Martelletti P; Cortelli P
J Headache Pain; 2017 Dec; 18(1):66. PubMed ID: 28667550
[TBL] [Abstract][Full Text] [Related]
2. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
Vernieri F; Paolucci M; Altamura C; Pasqualetti P; Mastrangelo V; Pierangeli G; Cevoli S; D'Amico D; Grazzi L
Headache; 2019 Sep; 59(8):1300-1309. PubMed ID: 31454075
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life.
Tassorelli C; Tedeschi G; Sarchielli P; Pini LA; Grazzi L; Geppetti P; De Tommaso M; Aguggia M; Cortelli P; Martelletti P
Expert Rev Neurother; 2018 Feb; 18(2):167-176. PubMed ID: 29280408
[TBL] [Abstract][Full Text] [Related]
4. The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.
Russo M; Manzoni GC; Taga A; Genovese A; Veronesi L; Pasquarella C; Sansebastiano GE; Torelli P
Neurol Sci; 2016 Jul; 37(7):1127-31. PubMed ID: 27048312
[TBL] [Abstract][Full Text] [Related]
5. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience.
Grazzi L; Usai S
Neurol Sci; 2015 May; 36 Suppl 1():33-5. PubMed ID: 26017508
[TBL] [Abstract][Full Text] [Related]
6. Onabotulinumtoxin A for prophylaxis in chronic migraine: preliminary data from Headache Regional Centre of Aosta Valley.
Lia C; Tosi P; Giardini G; Caligiana L; Bottacchi E
Neurol Sci; 2014 May; 35 Suppl 1():175-6. PubMed ID: 24867860
[TBL] [Abstract][Full Text] [Related]
7. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.
Bendtsen L; Sacco S; Ashina M; Mitsikostas D; Ahmed F; Pozo-Rosich P; Martelletti P
J Headache Pain; 2018 Sep; 19(1):91. PubMed ID: 30259200
[TBL] [Abstract][Full Text] [Related]
8. Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study.
de Tommaso M; Brighina F; Delussi M
Eur Neurol; 2019; 81(1-2):37-46. PubMed ID: 31013496
[TBL] [Abstract][Full Text] [Related]
9. Technique of injection of onabotulinumtoxin A for chronic migraine: the PREEMPT injection paradigm.
Liberini P; Pari E; Gazzina S; Caratozzolo S; Rao R; Padovani A
Neurol Sci; 2014 May; 35 Suppl 1():41-3. PubMed ID: 24867834
[TBL] [Abstract][Full Text] [Related]
10. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
Davies B; Gaul C; Martelletti P; García-Moncó JC; Brown S
J Headache Pain; 2017 Sep; 18(1):93. PubMed ID: 28879545
[TBL] [Abstract][Full Text] [Related]
11. Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment.
Grazzi L
Neurol Sci; 2017 May; 38(Suppl 1):141-143. PubMed ID: 28527077
[TBL] [Abstract][Full Text] [Related]
12. Survey on treatments for primary headaches in 13 specialized juvenile Headache Centers: The first multicenter Italian study.
Toldo I; Rattin M; Perissinotto E; De Carlo D; Bolzonella B; Nosadini M; Rossi LN; Vecchio A; Simonati A; Carotenuto M; Scalas C; Sciruicchio V; Raieli V; Mazzotta G; Tozzi E; Valeriani M; Cianchetti C; Balottin U; Guidetti V; Sartori S; Battistella PA
Eur J Paediatr Neurol; 2017 May; 21(3):507-521. PubMed ID: 28082014
[TBL] [Abstract][Full Text] [Related]
13. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
[TBL] [Abstract][Full Text] [Related]
14. Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data.
Ornello R; Guerzoni S; Baraldi C; Evangelista L; Frattale I; Marini C; Tiseo C; Pistoia F; Sacco S
J Headache Pain; 2020 Apr; 21(1):40. PubMed ID: 32334534
[TBL] [Abstract][Full Text] [Related]
15. What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group.
Sacco S; Russo A; Geppetti P; Grazzi L; Negro A; Tassorelli C; Tedeschi G; Martelletti P
Expert Rev Neurother; 2020 Dec; 20(12):1275-1286. PubMed ID: 32990477
[TBL] [Abstract][Full Text] [Related]
16. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Mitsikostas DD
J Headache Pain; 2016 Dec; 17(1):84. PubMed ID: 27640152
[TBL] [Abstract][Full Text] [Related]
17. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.
Lipton RB; Silberstein SD
Headache; 2015 Mar; 55 Suppl 2():103-22; quiz 123-6. PubMed ID: 25662743
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic migraine with intramuscular pericranial injections of onabotulinumtoxin a.
Belvis R; Mas N
Recent Pat CNS Drug Discov; 2014; 9(3):181-92. PubMed ID: 25643127
[TBL] [Abstract][Full Text] [Related]
19. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
[TBL] [Abstract][Full Text] [Related]
20. [Method of onabotulinumtoxin type A injection in chronic migraine: the PREEMPT protocol in clinical practice].
Latysheva NV; Naprienko MV; Filatova EG
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):93-96. PubMed ID: 34481443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
